MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145036 | Name: Guanazole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Guanazole is an RNR inhibitor. Guanazole is a cytostatic triazole derivative antimetabolite that scavenges tyrosine free radicals, thereby inhibiting mammalian ribonucleotide reductase activity and DNA synthesis.

Chemical Structure

Guanazole
Guanazole
CAS#1455-77-2

Theoretical Analysis

MedKoo Cat#: 145036

Name: Guanazole

CAS#: 1455-77-2

Chemical Formula: C2H5N5

Exact Mass: 99.0545

Molecular Weight: 99.10

Elemental Analysis: C, 24.24; H, 5.09; N, 70.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
GUANAZOLE; NSC-167391; MC 51762; NSC-166592; GUANAZOLE [INCI]; NSC-1895; NSC-167392;
IUPAC/Chemical Name
1H-1,2,4-triazole-3,5-diamine
InChi Key
PKWIYNIDEDLDCJ-UHFFFAOYSA-N
InChi Code
1S/C2H5N5/c3-1-5-2(4)7-6-1/h(H5,3,4,5,6,7)
SMILES Code
NC1=NC(N)=NN1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 99.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moore EC, Hurlbert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Pharmacol Ther. 1985;27(2):167-96. doi: 10.1016/0163-7258(85)90068-3. PMID: 3898152. 2: Alyahya MY, Khan S, Bhadra S, Samuel RE, Xu YJ. Replication stress induced by the ribonucleotide reductase inhibitor guanazole, triapine and gemcitabine in fission yeast. FEMS Yeast Res. 2022 Mar 24;22(1):foac014. doi: 10.1093/femsyr/foac014. PMID: 35262697; PMCID: PMC8951221. 3: Mys'kiv M, Goreshnik E. Bis[bis-(3,5-diamino-1H-1,2,4-triazol-4-ium)copper(I)] tris-(hexa- fluoridosilicate). Acta Crystallogr Sect E Struct Rep Online. 2010 Oct 23;66(Pt 11):m1453-4. doi: 10.1107/S160053681004225X. PMID: 21588872; PMCID: PMC3009260. 4: Dave C, Higby D, Mattern J, Holland JF, Grace JT. Pharmacokinetics of guanazole in patients with acute myelocytic leukemia. Clin Pharmacol Ther. 1975 Jan;17(1):36-43. doi: 10.1002/cpt197517136. PMID: 1054632. 5: Dias Selassie C, Lien EJ, Khwaja TA. Synthesis and evaluation of guanazole prodrugs as antineoplastic agents. J Pharm Sci. 1981 Nov;70(11):1281-3. doi: 10.1002/jps.2600701126. PMID: 7299678. 6: Zhang RB, Li ZJ, Qin YY, Cheng JK, Zhang J, Yao YG. Synthesis, structure, and physical properties of a new anions-controlled Cd(II)-guanazole (3,5-diamino-1,2,4-triazole) hybrid family. Inorg Chem. 2008 Jun 2;47(11):4861-76. doi: 10.1021/ic8001042. Epub 2008 May 2. PMID: 18452287. 7: Levi JA, Wiernik PH. A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Cancer. 1976 Jul;38(1):36-41. doi: 10.1002/1097-0142(197607)38:1<36::aid- cncr2820380107>3.0.co;2-m. PMID: 59627. 8: Caoili EM, Talley RW, Smith F, Salem P, Vaitkevicius VK. Guanazole (NSC-1895)--a phase I clinical study. Cancer Chemother Rep. 1975 Nov- Dec;59(6):1117-21. PMID: 769950. 9: Suter W, Romagna F. DNA repair induced by various mutagens in rat hepatocyte primary cultures measured in the presence of hydroxyurea, guanazole or aphidicolin. Mutat Res. 1990 Aug;231(2):251-64. doi: 10.1016/0027-5107(90)90031-x. PMID: 2117252. 10: Land VJ, Falletta JM, McMillan CW, Williams TE. Guanazole (NSC-1895) in the treatment of childhood leukemia. Cancer Chemother Rep. 1974 Sep-Oct;58(5 Pt 1):715-7. PMID: 4609600. 11: Hernández-Gil J, Ferrer S, Castiñeiras A, Liu-González M, Lloret F, Ribes A, Coga L, Bernecker A, Mareque-Rivas JC. Two novel ternary dicopper(II) μ-guanazole complexes with aromatic amines strongly activated by quantum dots for DNA cleavage. Inorg Chem. 2014 Jan 6;53(1):578-93. doi: 10.1021/ic4027249. Epub 2013 Dec 12. PMID: 24328056. 12: Vick JA, Herman EH. Cardiovascular effects of guanazole. Toxicol Appl Pharmacol. 1970 Jan;16(1):108-19. doi: 10.1016/0041-008x(70)90167-5. PMID: 5416741. 13: Krauss S, Broder LE, Birch R. Guanazole in the treatment of advanced bronchogenic carcinoma: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep. 1986 Jul;70(7):913-4. PMID: 3719585. 14: Paul MA, Dave C. A simple method for long-term drug infusion in mice: evaluation of guanazole as a model (38488). Proc Soc Exp Biol Med. 1975 Jan;148(1):118-22. doi: 10.3181/00379727-148-38488. PMID: 1129251. 15: Trevors JT. Evolution of bacterial genomes. Antonie Van Leeuwenhoek. 1997 Mar;71(3):265-70. doi: 10.1023/a:1000123216769. PMID: 9111921. 16: Yakar D, Holland JF, Ellison RR, Freeman A. Clinical pharmacological trial of guanazole. Cancer Res. 1973 May;33(5):972-5. PMID: 4512954. 17: Kolb VM, Dworkin JP, Miller SL. Alternative bases in the RNA world: the prebiotic synthesis of urazole and its ribosides. J Mol Evol. 1994;38:549-57. doi: 10.1007/BF00175873. PMID: 11539446. 18: Hewlett JS, Bodey GP, Coltman CA, Freireich EJ, Haut AB, McCredie KB. Intermittent guanazole therapy in adult acute leukemia. Clin Pharmacol Ther. 1973 Mar-Apr;14(2):271-6. doi: 10.1002/cpt1973142271. PMID: 4571981. 19: Lewis WH, Wright JA. Genetic characterization of hydroxyurea-resistance in Chinese hamster ovary cells. J Cell Physiol. 1978 Oct;97(1):73-85. doi: 10.1002/jcp.1040970108. PMID: 568629. 20: Gerber N, Seibert R, Desiderio D, Thompson RM, Lane M. Pharmacokinetics of guanazole in man. Clin Pharmacol Ther. 1973 Mar-Apr;14(2):264-70. doi: 10.1002/cpt1973142264. PMID: 4695387.